Goldman Sachs analyst Paul Choi initiated Spyre Therapeutics (SYRE) with an early-stage biotech designation. The firm sees an “attractive mix of clinically validated targets” and long-acting ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback